患者様やご家族など一般の方向け臨床・治癒情報サイト　臨床研究情報ポータルサイト

• 進捗状況
• 試験名
• 対象疾患名
• 地域
• 登録日
•  

• Authorised

• Treating learning disabilities in Neurofibromatosis 1 using lamotrigine
• Neurofibromatosis type 1 br>MedDRA version: 17.0 Level: LLT Classification code 10029270 Term: Neurofibromatosis, type 1 (von Recklinghausen's disease) System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
• Netherlands
• 2013-09-20

• Authorised

• The effect of interleukin-1 receptor antagonist on insulin secretion - Anakinra and insulin secretion
• Beta-cell dysfunction MedDRA version: 12.1 Level: LLT Classification code 10052341 Term: Impaired insulin secretion
• Netherlands
• 2010-06-10

• Authorised

• Treatment of symptomatic plexiform neurofibromas, a benign tumour associated with the disorder Neurofibromatosis type 1, in children with the drug trametinib
• NF1-related plexiform neurofibroma;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
• Sweden
• 2018-07-31

• Authorised

• First line TIP in poor prognosis TGCTs
• Disseminated Non-Seminomatous Germ Cell Tumors.;Therapeutic area: Diseases [C] - Cancer [C04]
• Slovakia
• 2015-04-09

• Authorised

• De effects of the bloodglucose lowering drugs exenatide (GLP-1 receptor agonist) and dapagliflozine ( a SGLT2 inhibitor) on the brain, food intake and bodyweight.
• Type 2 diabetes mellitus Obesity;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
• Netherlands
• 2017-08-14

• Authorised

• Assessment of glycemic compensation and hemodynamic parameteres in patients after administration of GLP-1 agonist exenatid during and after the implantation of aortocoronary by-pass.
• Patients with elective coronary artery bypass grafting with LV systolic dysfunction (EF LV = 50%) MedDRA version: 14.1 Level: PT Classification code 10011077 Term: Coronary artery bypass System Organ Class: 10042613 - Surgical and medical procedures MedDRA version: 14.1 Level: HLT Classification code 10012602 Term: Diabetes mellitus (incl subtypes) System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
• Czech Republic
• 2011-01-26

• Authorised

• Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, with a FRC extension period
• Type 2 Diabetes Mellitus MedDRA version: 20.0 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
• Canada, Estonia, Germany, Israel, Italy, Romania, Slovakia, Spain, United States
• 2016-05-10

• Authorised

• Effects of atorvastatin on plasma fibrin gel structure and skin microvascular reactivity in patients with type 1 diabetes and dyslipidemia - atorvastatin and fibrin gel structure
• Hyperlipidemia in patients with diabetes seems associated with a thrombogenic plasma fibrin gel structure and impaired microvascular function. We hypothesize that lipid lowering with a statin leads to the formation of a more porous and less thrombogenic fibrin network in turn leading to improved microvascular function. This may contribute to the positive effect of statins on vascular complications.
• Sweden
• 2004-09-16

• Authorised

• Studies on the effect of hyperglycemia on the structure of the fibrin-gel and on the glycosylation of fibrin , and in what way the use of acetylsalicylic acid may interfere with this effect. - Effect of ASA on the fibrin-gel.
• Patients with type 1 diabetes, not on ASA for the last 6 months, without a history of bleeding disorder and with a normal trobocyte count.
• Sweden
• 2005-12-22

• Authorised

• Anakinra versus treatment as usual in the treatment of acute gout
• Gout;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
• Netherlands
• 2015-06-12